<?xml version="1.0" encoding="UTF-8"?>
<p>Patient inclusion criteria consisted of the following: age 18 to 70 years, diagnosis of nonischemic DCM according to European Society of Cardiology position statement 
 <xref rid="sct312271-bib-0008" ref-type="ref">8</xref>, optimal medical management for ≥3 months, left ventricular ejection fraction (LVEF) &lt;40%, and New York Heart Association functional class III for ≥3 months before referral. Patients with acute multiorgan failure, a history of hematologic neoplasms, diminished functional capacity due to noncardiac comorbidities (chronic obstructive pulmonary disease, peripheral artery occlusive disease, morbid obesity), or pregnancy were not included. Informed consent was obtained in all patients prior to participation in the study, and the study protocol was approved by the National Medical Ethics Committee. The trial was registered with the European Medical Agency (EudraCT 002153‐38).
</p>
